Target XRN2, an exoribonuclease, suggests that our prioritized subnetwork confers some of its phenotype-defining effects through alteration in the DNA damage response, known to be mediated through Ku70 in LN229 and other GBM cells34. Here, XRN2 is linked to glioblastoma.